We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cellular Energy Regulation Key to Fighting Cancer

By Biotechdaily staff writers
Posted on 01 Sep 2005
In an attempt to combat disease by modifying energy regulation of cells, a collaborative study has shown that cells lacking a tumor-suppressing kinase called LKB1 can still maintain healthy energy levels when they become stressed. More...


This energy management is needed for keeping cells from dying off too soon. The study's findings could lead to new advances for fighting cancer, in addition to potential treatments for type 2 diabetes and obesity.

The study, published in the August 12, 2005, issue of the Journal of Biological Chemistry, was led by Dr. Lee Witters, from Dartmouth University Medical School (DMS, Hanover, NH, USA). Kinases include a large family of enzyme proteins that play major roles in the functioning of most cells in living organisms. Dr. Witters has focused much of his research on the AMP-activated kinase (AMPK), which is responsible for regulating energy within cellular pathways.

"A cell's energy level is critical to its survival,” explained Dr. Witters, who compared a low-energy cell to a car with an empty tank. "In a previous study, we found that the cellular ‘gas gauge,' AMPK, can turn around and alter any deficits in the cell if it is turned on by the kinase LKB1. In this study, we wanted to see if AMPK could also be turned on by something besides LKB1.”

"We decided to work with cervical and lung cancer cells because LKB1 is absent from the cellular pathway,” said Rebecca Hurley, lead author of the study and a graduate student in the molecular and cellular biology program at Dartmouth. Working closely with scientists at St. Vincent's Institute (Victoria, Australia) and Duke University (Durham, NC, USA), the DMS team concluded that two kinases in these cancer cells, CaMKKa and CaMKKß, are able to regulate AMPK independent of LBK1.

"With the addition of these two kinases, we think we have all nearly the players responsible for energy regulation within the cell, which should offer new opportunities in cancer treatment,” added Ms. Hurley. "If we can stifle a cancer cell's ability to adapt to an energy deficit, it might lose its growth advantage.”

"You need to know how all these proteins interact before you can make truly significant advances,” noted Dr. Witters "It's like poker; not only do you need to know what each card signifies individually, but you must have an understanding of how they play off each other in order to win.”

In addition to cancer-fighting potential of AMPK regulation, the enzyme also reacts to alterations in glucose or insulin and mediates faulty energy metabolism, a characteristic of type 2 diabetes. "This indicates that AMPK is a very tempting target for the treatment of some forms of diabetes and even obesity,” stated Dr. Witters.

As these investigators continue to narrow in on the key role of kinases in the treatment of disease, they recognize that this study is becoming more complicated and multiple approaches are needed to find solutions. Dr. Witters believes that major breakthroughs in science can only be achieved through open collaboration, citing partnerships between faculty and students, and between other institutes in the scientific and medical communities.

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.